Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "systemic lupus erythematosus (SLE)"

New SLE Drug May Allow Patients to Reduce Steroid Use

Michele B. Kaufman, PharmD, BCGP  |  December 16, 2015

In a recent study, the use of anifrolumab in SLE patients was shown to be safe and effective, enabling some patients to decrease their oral steroids. Also, secukinumab has been approved in Europe to treat ankylosing spondylitis and psoriatic arthritis…

Gene Expression Markers in T Cells Help Identify SLE Patient Subtypes

Lara C. Pullen, PhD  |  December 7, 2015

Researchers used T cell transcriptome analysis in a small-scale study, identifying gene expression of specific patient subtypes and finding that expression alteration of T cells may correlate with severity of SLE rather than its presentation…

Oxycodone Capsules Put on Hold; Clinical Trials for Lupus Nephritis & SLE Therapies

Michele B. Kaufman, PharmD, BCGP  |  November 25, 2015

Due to a lawsuit, the FDA has issued only tentative approval for an extended-release oxycodone capsule. Obinutuzumab is in clinical trials for lupus nephritis, and subcutaneous belimumab is being tested for SLE…

SLE—It’s in the Genes

Lara C. Pullen, PhD  |  November 23, 2015

In a large-scale genome-wide association study, researchers mapped 10 new SLE-associated loci and found aberrantly regulated gene expression networks may be behind SLE development…

Ro60 Autoantigen Regulates Inflammatory Gene Expression

Lara C. Pullen, PhD  |  November 9, 2015

New research links the RNA binding protein Ro60 with SLE pathogenesis and disease-causing inflammation…

Tabalumab Modestly Effective in Systemic Lupus Erythematosus

Will Boggs, MD  |  October 7, 2015

NEW YORK (Reuters Health)—Tabalumab, a monoclonal antibody to B-cell activating factor, was modestly better than placebo in relieving symptoms of systemic lupus erythematosus (SLE), according to results from the ILLUMINATE-2 trial. “Lupus is a complicated disease that does not behave the same way in all patients who share the clinical symptoms,” Dr. Joan T. Merrill…

How Hospitals Rank in Treating Childhood-Onset SLE

Richard Quinn  |  October 6, 2015

A recent study of how medical facilities in three countries meet minimum care standards for patients with childhood-onset systemic lupus erythematosus found a wide variation in quality of care…

Understanding SLE-Associated Skin Injury May Open the Door to Therapies

Lara C. Pullen, PhD  |  September 7, 2015

In a recent review, researchers addressed skin injury in patients with SLE, discussing the effects of ultraviolet rays on the skin and the subsequent generation of autoantibodies. They concluded that UV rays activate immune cells where IgG has been deposited, resulting in inflammation…

Epratuzumab Results Disappointing, but Adalimumab Promising

Michele B. Kaufman, PharmD, BCGP  |  August 19, 2015

Two Phase 3 trials have shown that epratuzumab did not meet its primary endpoints for treating SLE. Meanwhile, a Phase 3 study has shown adalimumab is effective for treating enthesitis-related arthritis in juveniles…

Brentuximab Vedotin Enters Phase 2 Trials & More

Michele B. Kaufman, PharmD, BCGP  |  August 5, 2015

Phase 2 clinical trials have begun to assess the safety of brentuximab vedotin for the treatment of SLE. Also, the FDA is reviewing an application for a once-daily tofacitinib citrate tablet to treat RA…

  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences